PRELIMINARY SCIENTIFIC PROGRAM

Subject to changes – as of November 5, 2023

	SATURDAY,MARCH 23,2024			
08:20-11:00	Amyotrophic lateral sclerosis (ALS)	HALL	Α	
Chairs:	TBA			
08:20-09:10	Is primary lateral sclerosis part of the ALS continuum or a different disease?			
	Capsule: to asks Vivian			
08:20-08:30	Moderator: <u>Albert Ludolph</u> , Germany Introduction and Pre-Debate Voting			
08:30-08:45	Yes: <u>Vivian Drory</u> , Israel			
08:45-09:00	No: TBA			
09:00-09:10	Discussion, Rebuttals and Post-Debate Voting			
09:10-10:00	Braak stages in ALS are supported by the facts			
	Capsule:			
09:10-09:20	Moderator: TBA			
	Introduction and Pre-Debate Voting			
09:20-09:35	Yes: <u>Albert Ludolph</u> , Germany			
09:35-09:50	No: TBA			
09:50-10:00	Discussion, Rebuttals and Post-Debate Voting			



The 18th World Congress on CONTROVERSIES IN NEUROLOGY

March 21-23, 2024 | London, UK

X 131 12	The second secon
10:00-11:00	ALS treatments have to demonstrate efficacy on both prolonging survival and slowing disease progression
	Capsule:
10:00-10:10	Moderator: TBA
	Introduction and Pre-Debate Voting
10:10-10:25	Yes: <u>Albert Ludolph,</u> Germany
10:25-10:40	No: TBA
10:40-11:00	Discussion, Rebuttals and Post-Debate Voting
11:00-11:30	Coffee Break, Exhibition & e-Posters Visit
	Plenary Session (Hall A)
	Aphantasia – when all is dark in the mind's eye
11:30-12:30	Adam Zeman, UK
	Neurological manifestation of Post COVID
	Mike Zandi, UK
12:30-13:30	Industry Sponsored Symposium (Hall A)
13:30-14:10	MTE
13:30-14:10	Lunch Break, Exhibition & e-Posters Visit
14:10- 16:10	ALS 2
Chairs:	TBA
14:30-15:20	The euphoria on personalized ALS treatment with Antisense oligonucleotides (ASO) is premature
	Capsule: Pam Shaw to wire capsule
14:30-14:40	Moderator: Osman Sinanovic
	Introduction and Pre-Debate Voting
14:40-14:55	Yes: <u>Pam Shaw,</u> UK
14:55-15:10	No: TBA
15:10-15:20	Discussion, Rebuttals and Post-Debate Voting



The 18th World Congress on CONTROVERSIES IN NEUROLOGY

March 21-23, 2024 | London, UK

15:20-16:10	Tracheostomy ventilation in ALS/MND should be offered to all patients.		
	Capsule:		
15:20-15:30	Moderator: Pam Shaw, UK Introduction and Pre-Debate Voting		
15:30-15:45	Yes: TBA		
15:45-16:00	No: TBA		
16:00-16:10	Discussion, Rebuttals and Post-Debate Voting		
16:10-16:30	Coffee Break, Exhibition & e-Posters Visit		
16:10-17:201	Neurodegenerative diseases		
Chairs:			
16:30-17:20	Will anti-tau drugs be useful in fighting tau-driven diseases?		
	Capsule:		
16:30-16:40	Moderator: TBA		
	Introduction and Pre-Debate Voting		
16:40-16:55	Yes: Lea Grinberg , USA		
16:55-17:10	No: TBA		
17:10-17:20	Discussion, Rebuttals and Post-Debate Voting		
17:20-18:10	Pathological changes in microglia were linked to pathology in different neurodegenerative diseases. Can we target microglia to develop a therapeutic approach?		
	Capsule:		
17:20-17:30	Moderator: TBA		
	Introduction and Pre-Debate Voting		
17:30-17:45	Yes: Dan Frenkel, Israel		
17:45-18:00	No : TBA		
18:00-18:10	Discussion, Rebuttals and Post-Debate Voting		

